Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib

NCT00441155 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG: Nilotinib, Imatinib

Sponsor

Novartis Pharmaceuticals